Gene
BCL6
BCL6 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (51), Actionable biomarkers (1), Trial mentions (251), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention BCL6. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 6 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 16 of 8,738 | 0.18% | not measured | |
| 2025 | 24 of 8,875 | 0.27% | not measured | |
| 2024 | 23 of 8,597 | 0.27% | not measured | |
| 2023 | 28 of 8,275 | 0.34% | 27 of 11,460 | 0.24% |
| 2022 | 31 of 8,285 | 0.37% | 33 of 13,598 | 0.24% |
| 2021 | 33 of 8,692 | 0.38% | 20 of 15,045 | 0.13% |
| 2020 | 22 of 7,640 | 0.29% | 33 of 14,459 | 0.23% |
| 2019 | 17 of 7,300 | 0.23% | 18 of 12,159 | 0.15% |
| 2018 | 24 of 6,927 | 0.35% | 23 of 11,854 | 0.19% |
| 2017 | 12 of 6,558 | 0.18% | 22 of 11,595 | 0.19% |
Showing 10 of 37 years.
Assay-provider ledger (51)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| NanoString Technologies | Unclassified | Clinical validationAnalytical validation | 1 | July 01, 2026 |
| Life Technologies | Reagent supplier | Clinical validation | 2 | August 26, 2025 |
| QIAGEN | Reagent supplier | Clinical validationAnalytical validation | 5 | August 26, 2025 |
| THERMO FISHER SCIENTIFIC (Click-iT EdU kit, TaqMan Low-Density Array reagents, ExpressionSuite/DataAssist software) | Reagent supplier | Clinical validation | 1 | August 26, 2025 |
| Advanced Molecular Diagnostic Laboratory, Princess Margaret Cancer Centre, University Health Network | Not a company | Analytical validation | 1 | February 18, 2025 |
Showing 5 of 51 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| BCL6 overexpression | Onalespib | response-associated | lymphoma | Cancer Genome Interpreter |
Trial mentions (251)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT07713797 | Trial biospecimen (AACT) |
| NCT03719989 | Trial eligibility (AACT) |
| NCT01193842 | Trial eligibility (AACT) |
| NCT05755087 | Trial eligibility (AACT) |
| NCT05800366 | Trial eligibility (AACT) |
Showing 5 of 251 trial mentions.
Target-disease associations (754)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| AIDS | genetic, familial or congenital disease | Literature (Europe PMC) |
| Abnormal thrombosis | phenotype | GWAS credible sets |
| Abruptio Placentae | pregnancy or perinatal disease | GWAS credible sets |
| Allergy | phenotype | Literature (Europe PMC) |
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
Showing 5 of 754 associations.
Vendor sourcing (763)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : 1. Men and women aged 18 years or older at the time of signing informed consent. 2. Able and willing to sign the informed consent form (ICF). 3. Ability t... | View trial NCT06919939 |
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * PART 1: Subjects must have a histologically confirmed diagnosis of diffuse large B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL) not oth... | View trial NCT05228249 |
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Histologically or cytologically confirmed untreated DEL and DHL diffuse large B-cell lymphoma (DLBCL) meeting the World Health Organization (WHO) criter... | View trial NCT05600686 |
| ADC Therapeutics SA | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Subject aged ≥ 18 years. * Intended to receive commercial CD19-directed CAR-T cell therapy (axi-cel and liso-cel). * Need for bridging therapy as deemed... | View trial NCT06788964 |
| ADC Therapeutics SA | Trial collaborator | Mentioned in trial textTrial free-text mention | BCL6 | View trial NCT06788964 |
Showing 5 of 763 sourcing records.
Trial-cited literature (322)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2025 | 12 |
| Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial. | Nature medicine | 2024 | 92 |
| Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma. | The New England journal of medicine | 2024 | 66 |
| Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma. | Blood advances | 2024 | 54 |
| Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study. | The Lancet. Haematology | 2024 | 30 |
Showing 5 of 322 papers.
Protein variant mentions (3)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.N50T | 1 | 2020 | PMID 31892985 |
| p.N80N | 1 | 2020 | PMID 31892985 |
| p.N90N | 1 | 2020 | PMID 31892985 |
Literature-extracted relations (44)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| RITUXIMAB | Chemical | positive_correlate |
Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. | 2018 |
| Progesterone | Chemical | associate |
KRAS Activation and over-expression of SIRT1/BCL6 Contributes to the Pathogenesis of Endometriosis and Progesterone Resistance. | 2017 |
| Calcium/Vitamin D | Chemical | associate |
Relevance of vitamin D receptor target genes for monitoring the vitamin D responsiveness of primary human cells. | 2015 |
| Niacinamide | Chemical | negative_correlate |
Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma. | 2013 |
| Anthracyclines | Chemical | positive_correlate |
Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. | 2001 |
Showing 5 of 44 relation assertions.
Organizations publishing (389)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 27 | 2004 to 2024 |
| The University of Texas System | Academic | 18 | 2011 to 2023 |
| Dana-Farber Cancer Institute | Other | 15 | 2009 to 2022 |
| Mayo Clinic | Hospital | 14 | 2011 to 2022 |
| Memorial Sloan Kettering Cancer Center | Hospital | 14 | 2015 to 2023 |
Showing 5 of 389 organizations.
Where BCL6 appears
- animal disease
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- injury, poisoning or other complication
- integumentary system disease
- measurement
- medical procedure
- musculoskeletal or connective tissue disease
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
- respiratory or thoracic disease
708 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.